Zynerba Pharmaceuticals, Inc. Sustainability Profile
Zynerba Pharmaceuticals, Inc., a pioneering biopharmaceutical company based in the United States, focuses on developing innovative cannabinoid-based therapies for neuropsychiatric conditions. Founded in 2007, Zynerba has made significant strides in the industry, particularly with its transdermal delivery systems that enhance the bioavailability of cannabinoids. The company’s flagship products, including Zygel, are designed to treat conditions such as autism spectrum disorder and osteoarthritis, setting Zynerba apart with their unique formulation and delivery methods. With a strong commitment to research and development, Zynerba has positioned itself as a leader in the cannabinoid therapeutics market, achieving notable milestones in clinical trials and regulatory advancements. As it continues to expand its operational footprint, Zynerba Pharmaceuticals remains dedicated to improving patient outcomes through innovative solutions.
DitchCarbon Score
How does Zynerba Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zynerba Pharmaceuticals, Inc.'s score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zynerba Pharmaceuticals, Inc.'s reported carbon emissions
Zynerba Pharmaceuticals, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established documented reduction targets or climate pledges, which suggests a lack of formalised commitments to reducing its carbon footprint. However, it is important to note that Zynerba Pharmaceuticals is a current subsidiary of Harmony Biosciences Holdings, Inc. This relationship may influence its climate strategy and reporting practices. As such, any potential climate initiatives or emissions data may be inherited from Harmony Biosciences, although specific details regarding emissions or targets from this parent company are not provided. In the broader context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and climate commitments. While Zynerba Pharmaceuticals has yet to disclose its own emissions or reduction initiatives, the industry trend towards transparency and accountability in carbon management may prompt future disclosures.
How Carbon Intensive is Zynerba Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Zynerba Pharmaceuticals, Inc.'s Location?
Zynerba Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zynerba Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
